Suchergebnisse - "Mah, Jean K"

PubPharm (203)

31

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

32

Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

33

Reldesemtiv in Patients with Spinal Muscular Atrophy : a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

ErratumIn: Neurotherapeutics. 2021 Jul;18(3):2130. - PMID 34731415

34

CHRNB1-associated congenital myasthenia syndrome : Expanding the clinical spectrum

enthalten in: American journal of medical genetics. Part A | 2021

von Freed, A. | Schwarz, A. | Brei, B. | +7

35

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

36

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: Neurotherapeutics | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

37

Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

enthalten in: NeuroRX | 2021

von Rudnicki, S. | Andrews, J. | Duong, T. | +20

38

Corrigendum to "Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy" [Neuromuscular Disorders, Vol. 30 (6) 2020, 492-502

enthalten in: Neuromuscular disorders : NMD | 2021

von Wagner, K. | Abdel-Hamid, H. | Mah, J. | +21

ErratumFor: Neuromuscul Disord. 2020 Jun;30(6):492-502. - PMID 32522498

39

CHRNB1‐associated congenital myasthenia syndrome : Expanding the clinical spectrum

enthalten in: American Journal of Medical Genetics Part C: Seminars in Medical Genetics | 2021

von Freed, A. | Schwarz, A. | Brei, B. | +7

40

Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada

enthalten in: Journal of medical economics | 2020

von Nakhaipour, H. | Vudumula, U. | Khurana, V. | +5